AstraZeneca's Dato-DXd significantly improved PFS in lung cancer
AstraZeneca's Dato-DXd significantly improved PFS in lung cancer
Source: directorstalkinterviews.com
Page 3 - Lung Fact News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lung Fact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lung Fact Today - Breaking & Trending Today
Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial
Positive high-level results from the TROPION-Lung01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with ...
Source: pharmiweb.com
Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial
In previously untreated patients, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy demonstrated objective response rates of 57%... | June 5, 2023
Source: marketscreener.com
TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
Treatment with adjuvant TAGRISSO reduced the risk of death by more than half ... | June 4, 2023
Source: marketscreener.com
AstraZeneca: TAGRISSO achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
Treatment with adjuvant TAGRISSO reduced the risk of death by more than half Positive results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) demonstrated a statistically
Source: finanznachrichten.de